Trial Search Results

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Collaborator: Stanford University

Stanford Investigator(s):


  • Drug: VTX-2337 plus radiotherapy


Phase 1/Phase 2


Major Inclusion Criteria:

   - low grade B cell lymphoma

   - 1 or more sites of disease appropriate for intratumoral injection

   - measurable disease other than the injection site

   - Performance Status of 1 or better

   - Adequate bone marrow, renal and hepatic function

   - No active autoimmune disease or systemic immunosuppressive drugs

   - Life expectancy > 4 months

Exclusion Criteria:

   - Known HIV

   - Known brain metastases

   - Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)

   - Anticoagulation therapy other than 325mg QD ASA

   - Significant cardiovascular disease

   - Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lori Richards
Not Recruiting